Annoying Roll-Out of Vaccines in Europe may Force Member Nations to Look for Alternatives
The European Union and its member nations have been heavily criticized for their efforts in ensuring that Covid-19 vaccination goes on smoothly in the continent.
The biggest share of the fire has come from citizens who blame administrators for laxity in this regard. In response, many of the administrators under fire have shifted the blame to the pharmaceutical manufacturers who have more than they can handle.
Newer Alternatives Are Being Sought
Most of the population has not been vaccinated. The situation is even more complicated considering that proper vaccination required the administration of 2 jabs of the dose.
As a result, the administrators at the European Union and its member nations are seeking alternatives. This is since the rollout of vaccines by few pharmaceuticals is insufficient in meeting the rising demand for the vaccines.
A while ago, information reaching this news outfit indicated that the European Union and its member nations are considering getting Johnson and Johnson pharmaceuticals on board. The decision of the United States Food and Drug Administration in approving the vaccines of this pharmaceutical industry may have set this precedence.
Will the Decision to Use Johnson and Johnson Vaccines Pull Through
While the European Union and its member nations need all the help they can get in terms of vaccination, the Johnson and Johnson vaccine is peculiar in many regards. For instance, although safe, it is not as potent as many other alternatives as discovered by the FDA.
However, it is great in the sense that it is a single dose. This means that the political administrators and healthcare workers will have fewer worries. This is because there will be no need for a second dose.
In the same development, it should be noted that the European Union and its member nations are also considering engaging vaccines from Israel and even Russia. The fate of the vaccination program in this regard will be determined in the next few weeks at most.